Replimune Group Inc., a Woburn, MA-based biotechnology company focused on developing next generation oncolytic immunotherapies, completed a $55m Series B financing.
The round was led by Foresite Capital with participation from Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management, entities affiliated with Leerink Partners, Atlas Venture, Forbion Capital Partners, and Omega Funds. In conjunction with the funding, Dr. Brett Zbar from Foresite Capital will join Replimune’s board of directors, as will Dr. Kapil Dhingra, previously head of clinical oncology at Roche, and currently an advisor to the company.
The company intends to use the proceeds to generate human proof of concept data for its lead product, RP1, in multiple tumor types, and to advance further product candidates from its Immulytic™ platform.
Led by Dr. Robert Coffin, CEO, and Howard Kaufman, CMO, Replimune Group develops ‘oncolytic immunotherapies’ for the treatment of cancer. It is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Its Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes.